HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

VEGFA +936C>T polymorphism and cancer risk: a meta-analysis.

Abstract
Vascular endothelial growth factor A (VEGF-A), a major driver of physiological and pathological angiogenesis, plays important roles in the etiology and metastasis of cancers. The +936C>T polymorphism in the 3'-untranslated region of the VEGFA gene has been implicated in cancer risk and is related to VEGF-A protein production; however, published data have been conflicting. To derive a more precise estimation of the relationship, a meta-analysis was performed of 13,293 cancer cases and 12,308 control subjects from 29 published case-control studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between +936C>T polymorphism and cancer risk. The meta-analysis indicated that individuals with the +936 T had increased risk of oral cancer (OR = 1.39, 95% CI = 1.03-1.88), although no association was found in the contrast of T versus C (OR = 1.00, 95% CI = 0.91-1.10) in the pooled analyses. This meta-analysis supports the idea that VEGFA + 936 T is associated with increased risk of oral cancer. To draw comprehensive and true conclusions, further prospective studies with larger numbers of participants worldwide are needed to examine associations between VEGFA + 936C>T polymorphism and cancer risk.
AuthorsBin Xu, Jiu-Ming Li, Na Tong, Jun Tao, Peng-Chao Li, Ning-Hong Song, Wei Zhang, Hong-Fei Wu, Ning-Han Feng, Li-Xin Hua
JournalCancer genetics and cytogenetics (Cancer Genet Cytogenet) Vol. 198 Issue 1 Pg. 7-14 (Apr 01 2010) ISSN: 1873-4456 [Electronic] United States
PMID20303008 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2010 Elsevier Inc. All rights reserved.
Chemical References
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
Topics
  • Humans
  • Mouth Neoplasms (genetics)
  • Polymorphism, Genetic
  • Risk
  • Vascular Endothelial Growth Factor A (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: